Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 0.60 |
| ▸ | PDE6D | O43924 | 1/20 | 0.60 |
| ▸ | PDE6A | P16499 | 1/20 | 0.60 |
| ▸ | PDE6G | P18545 | 1/20 | 0.60 |
| ▸ | PDE6B | P35913 | 1/20 | 0.60 |
| ▸ | PDE6C | P51160 | 1/20 | 0.60 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ATF1 | P18846 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4428236 | 0.94 | PDE5A (0.56) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL649687 | 0.91 | PDE5A (0.60) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL4743428 | 0.89 | KMT2A (0.53) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL263314 | 0.89 | KMT2A (0.53) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL14378112 | 0.88 | THRB (0.62) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL430575 | 0.87 | THRB (0.61) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL437005 | 0.86 | THRB (0.60) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL18987698 | 0.85 | TP53 (0.54) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL621104 | 0.84 | KMT2A (0.55) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL7069841 | 0.84 | THRB (0.58) | PDE5APDE6DPDE6APDE6GPDE6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11427582-B2 | Ligands selective to alpha 6 subunit-containing GABAA receptors and their methods of use | UWM RESEARCH FOUNDATION, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20210047322-A1 | LIGANDS SELECTIVE TO ALPHA 6 SUBUNIT-CONTAINING GABAA RECEPTORS AND THEIR METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-02-18 | — | — | US | disclosed |
| US-10865203-B2 | Ligands selective to alpha 6 subunit-containing GABAA receptors and their methods of use | UWM RESEARCH FOUNDATION, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| EP-3325479-B1 | LIGANDS SELECTIVE TO ALPHA 6 SUBUNIT-CONTAINING GABAA RECEPTORS AND THEIR METHODS OF USE | UWM RES FOUNDATION INC (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3325479-A1 | LIGANDS SELECTIVE TO ALPHA 6 SUBUNIT-CONTAINING GABAa RECEPTORS ANS THEIR METHODS OF USE | UWM Research Foundation, Inc. (US) | 2018-05-30 | — | — | EP | disclosed |
| US-20180134698-A1 | LIGANDS SELECTIVE TO ALPHA 6 SUBUNIT-CONTAINING GABAA RECEPTORS AND THEIR METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-05-17 | — | — | US | disclosed |
| WO-2016196961-A1 | LIGANDS SELECTIVE TO ALPHA 6 SUBUNIT-CONTAINING GABAA RECEPTORS ANS THEIR METHODS OF USE | UWM RESEARCH FOUNDATION, INC. (US) | 2016-12-08 | — | — | WO | disclosed |
| US-20130165479-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBVIE, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8350083-B2 | Antagonists of the TRPV1 receptor and uses thereof | ABBVIE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2450346-A1 | Antagonists of the TRPV1 receptor and uses thereof | Abbott Laboratories (US) | 2012-05-09 | — | — | EP | disclosed |
| EP-1157024-A1 | ACETYLENIC ORTHO-SULFONAMIDO AND PHOSPHINIC ACID AMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS TACE INHIBITORS | American Cyanamid Company (US) | 2001-11-28 | — | — | EP | disclosed |
| US-20010025047-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors | WYETH HOLDINGS CORPORATION | 2001-09-27 | — | — | US | disclosed |
| US-6228869-B1 | ANTITUMOR, ANTIMETASTASIS, ANTIARTHRITIC, AND WOUND HEALING AGENTS; QUINOLINE AND ISOQUINOLINE DERIVATIVES | AMERICAN CYANAMID COMPANY | 2001-05-08 | — | — | US | disclosed |
| CN-1280568-A | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors | AMERICAN CYANAMID CO (US) | 2001-01-17 | — | — | CN | disclosed |
| WO-2000044749-A1 | ACETYLENIC ORTHO-SULFONAMIDO AND PHOSPHINIC ACID AMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| EP-1021413-A1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | American Cyanamid Company (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-1999018076-A1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-04-15 | — | — | WO | disclosed |
| WO-1998016514-A1 | ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1998-04-23 | — | — | WO | disclosed |
| US-5026711-A | Prevention and treatment of cardiovascular disorders and infections states; anxiolytic and anti-allergic agents | SANOFI (FR) | 1991-06-25 | — | — | US | disclosed |
| US-4735952-A | ANTI-HYPERTENSIVE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047322-A1 | LIGANDS SELECTIVE TO ALPHA 6 SUBUNIT-CONTAINING GABAA RECEPTORS AND THEIR METHODS OF USE | GABRA6, HTR6, GABRD | PDE5A 1110/4885PDE6D 1404/4885PDE6A 454/4885 |
| US-20180134698-A1 | LIGANDS SELECTIVE TO ALPHA 6 SUBUNIT-CONTAINING GABAA RECEPTORS AND THEIR METHODS OF USE | GABRA6, HTR6, GABRD | PDE5A 1085/4885PDE6D 1348/4885PDE6A 477/4885 |
| US-11427582-B2 | Ligands selective to alpha 6 subunit-containing GABAA receptors and their methods of use | GABRA6, HTR6, GABRD | PDE5A 1110/4885PDE6D 1404/4885PDE6A 454/4885 |
| US-20130165479-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | PDE5A 1820/4885PDE6D 1225/4885PDE6A 1486/4885 |
| US-10865203-B2 | Ligands selective to alpha 6 subunit-containing GABAA receptors and their methods of use | GABRA6, HTR6, GABRD | PDE5A 1085/4885PDE6D 1348/4885PDE6A 477/4885 |
| US-20010025047-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors | MSR1, TIMP3, TGFBR2 | PDE5A 4815/4885PDE6D 4848/4885PDE6A 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.